Targeted RNAi Molecule Platform Market

GalNAc-conjugated siRNA leads the platform technology category with 33.4% share in 2026, while hepatic targets account for 33.0% of target type share. Cardiometabolic diseases hold 30.4% of application share, supported by established liver delivery, measurable endpoints, durable gene silencing, and broader clinical development.